Cytotoxic therapy with etoposide and cisplatin in advanced adrenocortical carcinoma

R Bonacci, A Gigliotti, E Baudin, N Wion-Barbot, P Emy, M Bonnay, A F Cailleux, I Nakib, M Schlumberger, Réseau Comète, R Bonacci, A Gigliotti, E Baudin, N Wion-Barbot, P Emy, M Bonnay, A F Cailleux, I Nakib, M Schlumberger, Réseau Comète

Abstract

Adrenocortical carcinoma (ACC) is a rare tumour with a poor prognosis. Cisplatin is the most widely tested cytotoxic agent in this disease. A total of 18 patients with advanced ACC were enrolled. Cytotoxic therapy consisted of etoposide (VP16) (100 mg m(-2) day(-1) on days 1-3) and cisplatin (100 mg m(-2) day(-1) on day 1) every 4 weeks. Mitotane treatment was maintained during chemotherapy in 14 patients. A complete response was observed in three cases and a partial response in three cases, giving an overall response rate of 33%. Tumour response was observed in three of the six patients with progressive disease during treatment with mitotane given at an effective dosage, as shown by serum levels >14 mg l(-1). Toxic effects were as expected and were non-life-threatening; no treatment interruption was required.

References

    1. Am J Med. 1966 Oct;41(4):581-92
    1. Br J Cancer. 1994 May;69(5):947-51
    1. Cancer. 1981 May 1;47(9):2153-61
    1. Am J Med. 1981 Nov;71(5):855-75
    1. Cancer Treat Rep. 1983 Apr;67(4):377-9
    1. Cancer Treat Rep. 1983 May;67(5):513-4
    1. Cancer. 1984 Jan 1;53(1):26-9
    1. Cancer. 1986 Nov 15;58(10):2198-202
    1. Cancer Treat Rep. 1987 Feb;71(2):222-4
    1. N Engl J Med. 1990 Apr 26;322(17):1195-201
    1. Arch Surg. 1991 Apr;126(4):457-61
    1. Cancer. 1991 Jun 15;67(12):2997-3000
    1. World J Surg. 1992 Jul-Aug;16(4):753-8
    1. Surgery. 1992 Dec;112(6):963-70; discussion 970-1
    1. J Clin Oncol. 1993 Jan;11(1):161-5
    1. Med J Aust. 1980 May 3;1(9):419-21

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe